Prostate cancer mortality in the finnish randomized screening trial

Tuomas P. Kilpeläinen, Teuvo L. Tammela, Nea Malila, Matti Hakama, Henrikki Santti, Liisa Määttänen, Ulf Håkan Stenman, Paula Kujala, Anssi Auvinen

Research output: Contribution to journalArticleScientificpeer-review

74 Citations (Scopus)

Abstract

BackgroundProstate cancer (PC) screening with prostate-specific antigen (PSA) has been shown to decrease PC mortality by the European Randomized Study of Screening for Prostate Cancer (ERSPC). We evaluated mortality results in the Finnish Prostate Cancer Screening Trial, the largest component of ERSPC. The primary endpoint was PC-specific mortality.MethodsA total of 80 144 men were identified from the population registry and randomized to either a screening arm (SA) or a control arm (CA). Men in the SA were invited to serum PSA determination up to three times with a 4-year interval between each scan and referred to biopsy if the PSA concentration was greater than or equal to 4.0ng/mL or 3.0 to 3.99ng/mL with a free/total PSA ratio less than or equal to 16%. Men in the CA received usual care. The analysis covers follow-up to 12 years from randomization for all men. Hazard ratios (HRs) were estimated for incidence and mortality using Cox proportional hazard model. All statistical tests were two-sided.ResultsPC incidence was 8.8 per 1000 person-years in the SA and 6.6 in the CA (HR = 1.34, 95% confidence interval [CI] = 1.27 to 1.40). The incidence of advanced PC was lower in the SA vs CA arm (1.2 vs 1.6, respectively: HR = 0.73, 95% CI = 0.64 to 0.82: P

Original languageEnglish
Pages (from-to)719-725
Number of pages7
JournalJOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume105
Issue number10
DOIs
Publication statusPublished - 2013
Publication typeA1 Journal article-refereed

Publication forum classification

  • No publication forum level

Fingerprint Dive into the research topics of 'Prostate cancer mortality in the finnish randomized screening trial'. Together they form a unique fingerprint.

Cite this